KAMADA » INVESTORS » NEWS & EVENTS

NEWS & EVENTS

Latest News

Kamada Reports Financial Results for Second Quarter and First Six Months of 2018

Aug. 7, 2018

Kamada announced financial results for the three and six months
ended June 30, 2018.

Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

Jul. 10, 2018

Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).


Upcoming Events

Kamada to participate in ERS International Congress 2018

Sep. 15-19, 2018 / Paris, France

ERS congress is the largest meeting of respiratory professionals in the world, with an outstanding scientific and educational programme designed to address the needs of researchers, clinicians, general practitioners and allied health professionals alike.

Covering key topics in respiratory medicine from across the spectrum of disease areas including TB, lung cancer, chronic and acute respiratory failure, sleep breathing disorders, interstitial lung diseases, pneumonia, cystic fibrosis, COPD and asthma, amongst others, the congress programme is set to deliver the best advances in both science and education.

This years’ congress will specifically highlight the importance of environment in respiratory health and focus on the need to personalise medicine in the respiratory arena. Special attention will also be paid to our interactions with microorganisms in our environment as well as those that live in peace within our organism.


 

Kamada to participate in Immunology of Diabetes Society (IDS)

Oct. 25-29, 2018 / London, UK

The congress will include  talks on a wide range of current topics of interest to the community, which include ground-breaking technologies, cell-based and advanced therapeutics, immunopathology of type 1 diabetes, pathways to beta cell failure, updates from the Networks – nPod, TEDDY, Trialnet and the Immune Tolerance Network, as well as an adversarial debate and a “balloon debate”. There will be ample opportunities for networking and discussion, to move towards our common goal of understanding the immunology of type 1 diabetes and how we may intervene to change the course of disease.


Past Event

Kamada to participate in 78th Scientific Sessions ADA

Jun. 22-26, 2018 / Orlando, Florida

The Scientific Sessions offers researchers and health care professionals an amazing opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Over the course of five days, attendees will receive exclusive access to more than 2,800 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand professional networks with nearly 13,000 professional attendees from around the world.